“BRCA1 and BRCA2 [pathogenic or likely pathogenic variants] are the most common cause of hereditary ovarian cancer, but…in the past several years, we have learned a lot more about the other genetic contributions,” commented Leigha Senter, MS, CGC, Professor, Clinical Internal Medicine; Associate Director, Division of Human Genetics, The Ohio State University, and member of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Panel for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. At the NCCN 2023 Annual Conference, she discussed the current variants of concern, testing principles, and risk management strategies for hereditary ovarian cancer.
Daly MB, Pal T, AlHilli Z, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2023. Accessed April 9, 2023. To view the most recent version, visit https://www.nccn.org
Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015;136:3–7.
Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 2020;38:1222–1245.
Senter L, O’Malley DM, Backes FJ, et al. Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. Gynecol Oncol 2017;147:110–114.
Childers CP, Childers KK, Maggard-Gibbons M, et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 2017;35:3800–3806.
Bednar EM, Oakley HD, Sun CC, et al. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol 2017;146:399–404.
Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260–2265.
Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 2004;23:29–34.
Chen J, Bae E, Zhang L, et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis. JNCI Cancer Spectr 2020;4:pkaa029.
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:2402–2416.
Finch APM, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:1547–1553.
Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 2017;3:1190–1196.
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80–87.
Falconer H, Yin L, Grönberg H, et al. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015;107:dju410.